In non-small cell lung cancer (NSCLC), FGF/FGFR pathway activation, mediated by FGF2 and FGF9 signalling through FGFR1 or FGFR2, has been suggested to promote EGFR inhibitor resistance [76]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.